Global Biologic Excipients market size was valued at USD 2.45 billion in 2024. The market is projected to grow from USD 2.73 billion in 2025 to USD 4.92 billion by 2032, exhibiting a CAGR of 7.7% during the forecast period.

Biologic excipients are non-active substances used in biologic drug formulations to improve stability, bioavailability, and manufacturability. These pharmaceutical ingredients play vital roles in drug delivery systems, acting as stabilizers, bulking agents, binders, and coatings. The growing biologics market, increasing demand for targeted drug delivery, and advancements in formulation technologies are key drivers for biologic excipients adoption.

The biologic excipients market is experiencing robust growth due to the development of complex biologics like monoclonal antibodies, recombinant proteins, and cell/gene therapies. Regulatory support for biosimilars and the expansion of biopharmaceutical manufacturing capacity worldwide are further accelerating market expansion.

Read Full Report Here: https://www.24chemicalresearch.com/reports/215585/global-biologic-excipients-forecast-market-2023-2029-969

Segmentation by Product Type

The biologic excipients market is segmented into seven primary product categories based on chemical composition and functional properties:

1. Polymers

Polymeric excipients including polyethylene glycol (PEG), hydroxypropyl methylcellulose (HPMC), and polyvinylpyrrolidone (PVP) are widely used as viscosity modifiers, stabilizers, and drug carriers in biologic formulations.

• Market Insight: Polymers dominate the product segment with over 30% market share, driven by their versatility in various biologic formulations. PEGylation technology for protein therapeutics is particularly boosting demand.
• Trend: Increasing adoption of biodegradable polymers is emerging as a key trend, aligned with sustainability initiatives in pharmaceutical manufacturing.

2. Sugar Alcohols

Mannitol, sorbitol, and other sugar alcohols serve as cryoprotectants and bulking agents in lyophilized biologic formulations.

• Market Insight: This segment is growing at above-average rates due to increased production of freeze-dried biologics and vaccines. Mannitol’s superior crystallization properties make it particularly valuable.
• Trend: Demand is accelerating for ultra-pure, low-endotoxin grades to meet stringent biologic manufacturing requirements.

3. Polysorbates

Polysorbate 20 and 80 are the most commonly used surfactants in biologics to prevent protein aggregation and interfacial stress.

• Market Insight: Polysorbates account for significant revenue share due to their critical role in monoclonal antibody formulations. However, degradation concerns are driving innovation in alternative stabilizers.
• Trend: Manufacturers are developing polysorbate alternatives and improved analytical methods to monitor degradation in biologic products.

4. Inorganic Salts

Salts such as sodium chloride and potassium phosphate function as buffers and tonicity adjusters in biologics.

• Market Insight: While mature, this segment maintains stable demand due to the essential role of salts in maintaining biologic product stability and osmolality.
• Trend: Development of novel buffer systems for next-generation biologics is creating niche growth opportunities.

5. Amino Acids

Amino acids like histidine, arginine, and glycine serve as stabilizers, pH modifiers, and solubilizing agents.

• Market Insight: This is one of the fastest-growing segments, driven by increasing protein therapeutic development. Histidine is particularly important for monoclonal antibody formulations.
• Trend: Demand is shifting toward plant-derived amino acids to address emerging regulatory expectations.

6. Surfactants

Non-polysorbate surfactants are gaining traction as alternatives to traditional options.

• Market Insight: Still a relatively small segment but growing rapidly due to concerns about polysorbate degradation in biologics.
• Trend: Sophisticated surfactant blends are being developed specifically for sensitive biologic formulations.

7. Other Excipients

This category includes specialized additives like cyclodextrins and novel stabilizing agents.

• Market Insight: Accounts for about 15% of the market but includes some of the highest-value excipients for complex biologics.
• Trend: Increasing R&D investment in excipients for mRNA and cell therapy products is driving innovation.

Download FREE Sample Report: Biologic Excipients Market – View in Detailed Research Report

Segmentation by Application

Biologic excipients find application across three primary areas in the biopharmaceutical value chain:

1. Biopharmaceutical Manufacturers

Original biologic drug producers represent the largest application segment.

• Insight: Accounts for over 60% of total demand as excipients are integral to biologic drug formulation and manufacturing. Large molecule drugs like monoclonal antibodies consume significant excipient volumes.
• Trend: Increasing adoption of single-use technologies is modifying excipient requirements and specifications.

2. Contract Research Organizations/Contract Manufacturing Organizations

CROs and CMOs are major consumers of excipients for client projects.

• Insight: This segment is growing faster than the overall market as biologics outsourcing increases. CMOs specializing in biologics often maintain extensive excipient inventories.
• Trend: CMOs are increasingly involved in excipient selection and formulation optimization as part of development services.

3. Research Organizations

Academic and institutional researchers use excipients in biologic R&D.

• Insight: While smaller in volume, this segment is critical for early-stage excipient evaluation and innovation. Many novel excipient applications originate in research settings.
• Trend: Growing stem cell and gene therapy research is driving demand for specialized excipients in academic labs.

Segmentation by End-User

The market can be analyzed by the type of organizations using biologic excipients:

1. Large Biopharma Companies

• Insight: Dominant end-users with extensive in-house formulation capabilities. These companies often have long-term supply agreements with excipient manufacturers.
• Trend: Increasing focus on second-generation biologics is driving demand for advanced excipient systems.

2. Emerging Biotech Firms

• Insight: Fast-growing segment that often relies on CMOs for formulations. These companies tend to prioritize innovative excipient solutions.
• Trend: Many emerging players focus on niche biologic therapies with unique excipient requirements.

3. Academic and Government Research Institutes

• Insight: Important for early-stage excipient research and evaluation. Procurement is often through distributors rather than direct from manufacturers.
• Trend: Increased government funding for biologic research is supporting growth in this segment.

4. CDMOs/CMOs

• Insight: As outsourced biologic manufacturing grows, these organizations are becoming significant excipient consumers, often stocking materials for multiple clients.
• Trend: CDMOs are expanding their formulation expertise and excipient screening capabilities as a value-added service.

Read Full Report: Biologic Excipients Market – View in Detailed Research Report

Download FREE Sample Report: Biologic Excipients Market – View in Detailed Research Report